# Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC

> **NCT07754123** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 206 (estimated)

## Conditions studied

- Advanced or Metastatic NSCLC

## Interventions

- **DRUG:** HS-10504
- **DRUG:** platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin)

## Key facts

- **NCT ID:** NCT07754123
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-17
- **Primary completion:** 2028-08-31
- **Final completion:** 2031-07-31
- **Target enrollment:** 206 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07754123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07754123, "Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07754123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*